\u30cc\u30d9\u30fc\u30b7\u30e7\u30f3<\/a> \u30bf\u30ec\u30c8\u30ec\u30af\u30c1\u30cb\u30d6\u3092\u7c73\u56fd\u3001\u4e2d\u56fd\u3001\u65e5\u672c\u4ee5\u5916\u306e\u8907\u6570\u306e\u5730\u57df\u3067\u4f7f\u7528\u3067\u304d\u308b\u3088\u3046\u306b\u3059\u308b\u305f\u3081\u3067\u3059\u3002\u6b27\u5dde\u306f\u307e\u3055\u306b\u305d\u306e\u8a08\u753b\u306b\u8a72\u5f53\u3057\u307e\u3059\u3002\u3053\u306e\u5f8c\u3001\u82f1\u56fd\u3001\u30ab\u30ca\u30c0\u3001\u304a\u3088\u3073\u30a8\u30fc\u30b6\u30a4\u306e\u30e9\u30a4\u30bb\u30f3\u30b9\u5730\u57df\u5185\u306e\u4ed6\u306e\u5e02\u5834\u306b\u3082\u7533\u8acb\u3059\u308b\u4e88\u5b9a\u3067\u3059\u3002.<\/p>\n\u3067\u3059\u304b\u3089\u3001\u3053\u308c\u306f\u5358\u306a\u308b1\u56de\u306e\u627f\u8a8d\u3067\u306f\u3042\u308a\u307e\u305b\u3093\u3002\u3088\u308a\u5e83\u7bc4\u306a\u5c55\u958b\u306e\u4e00\u90e8\u306a\u306e\u3067\u3059\u3002\u3053\u306e\u85ac\u306f\u3059\u3067\u306b\u4e3b\u8981\u306a\u5e02\u5834\u3067\u6d41\u901a\u3057\u3066\u3044\u307e\u3059\u3002\u4eca\u306f\u3001\u6b8b\u308a\u306e\u5927\u304d\u306a\u5730\u57df\u3067\u627f\u8a8d\u3092\u53d6\u5f97\u3057\u3001\u4e00\u6b69\u4e00\u6b69\u3088\u308a\u5e83\u3044\u30d7\u30ec\u30bc\u30f3\u30b9\u3092\u7bc9\u3044\u3066\u3044\u304f\u3053\u3068\u3067\u3059\u3002.<\/p>","protected":false},"excerpt":{"rendered":"
Eisai Co., Ltd. and Nuvation Bio Inc. have pushed taletrectinib into the next stage in Europe. The European Medicines Agency has validated the application. That basically means the file is complete and now it moves into a full review under the standard timeline. This is not a fresh drug entering the system for the first time. Taletrectinib is already approved in the U.S., China, and Japan for advanced ROS1-positive non-small cell lung cancer. In the U.S. and Japan, it is sold as IBTROZI. In China, it is marketed as DOVBLERON. So the groundwork is already there. Europe is the next obvious step. The drug targets a specific mutation. ROS1-positive cases […]<\/p>\n","protected":false},"author":7,"featured_media":30531,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"wprm-recipe-roundup-name":"","wprm-recipe-roundup-description":"","postBodyCss":"","postBodyMargin":[],"postBodyPadding":[],"postBodyBackground":{"backgroundType":"classic","gradient":""},"footnotes":""},"categories":[89,207,237,182],"tags":[1715,12176,424,12174,12175],"ppma_author":[572],"class_list":{"0":"post-30530","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-health-tech","8":"category-international","9":"category-news","10":"category-pharma","11":"tag-eisai","12":"tag-nuvation-bio","13":"tag-pharma","14":"tag-ros1-positive","15":"tag-taletrectinib"},"yoast_head":"\n
Eisai and Nuvation Broaden Taletrectinib\u2019s EU Reach<\/title>\n<meta name=\"description\" content=\"Eisai and Nuvation Bio advance taletrectinib in Europe as the European Medicines Agency validates the application.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/taletrectinib-moves-toward-europe-approval-review\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eisai and Nuvation Broaden Taletrectinib\u2019s EU Reach\" \/>\n<meta property=\"og:description\" content=\"Eisai and Nuvation Bio advance taletrectinib in Europe as the European Medicines Agency validates the application.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/taletrectinib-moves-toward-europe-approval-review\/\" \/>\n<meta property=\"og:site_name\" content=\"itbusinesstoday\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-27T10:44:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2026\/03\/Eisai-and-Nuvation-Bio-Announce-Marketing-Authorisation-Application-for-Taletrectinib-for-the-Treatment-of-Advanced-ROS1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"ITBT StaffWriter\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"ITBT StaffWriter\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"2\u5206\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Eisai and Nuvation Broaden Taletrectinib\u2019s EU Reach","description":"Eisai and Nuvation Bio advance taletrectinib in Europe as the European Medicines Agency validates the application.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/taletrectinib-moves-toward-europe-approval-review\/","og_locale":"ja_JP","og_type":"article","og_title":"Eisai and Nuvation Broaden Taletrectinib\u2019s EU Reach","og_description":"Eisai and Nuvation Bio advance taletrectinib in Europe as the European Medicines Agency validates the application.","og_url":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/taletrectinib-moves-toward-europe-approval-review\/","og_site_name":"itbusinesstoday","article_published_time":"2026-03-27T10:44:58+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2026\/03\/Eisai-and-Nuvation-Bio-Announce-Marketing-Authorisation-Application-for-Taletrectinib-for-the-Treatment-of-Advanced-ROS1.webp","type":"image\/webp"}],"author":"ITBT StaffWriter","twitter_card":"summary_large_image","twitter_misc":{"\u57f7\u7b46\u8005":"ITBT StaffWriter","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"2\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/taletrectinib-moves-toward-europe-approval-review\/#article","isPartOf":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/taletrectinib-moves-toward-europe-approval-review\/"},"author":{"name":"ITBT StaffWriter","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/person\/94fb575e469aff25a4b938814d050f15"},"headline":"Taletrectinib Moves Toward Europe Approval Review","datePublished":"2026-03-27T10:44:58+00:00","mainEntityOfPage":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/taletrectinib-moves-toward-europe-approval-review\/"},"wordCount":336,"publisher":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization"},"image":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/taletrectinib-moves-toward-europe-approval-review\/#primaryimage"},"thumbnailUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2026\/03\/Eisai-and-Nuvation-Bio-Announce-Marketing-Authorisation-Application-for-Taletrectinib-for-the-Treatment-of-Advanced-ROS1.webp","keywords":["Eisai","Nuvation Bio","Pharma","ROS1-positive","Taletrectinib"],"articleSection":["Health Tech","International","News","Pharma"],"inLanguage":"ja"},{"@type":"WebPage","@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/taletrectinib-moves-toward-europe-approval-review\/","url":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/taletrectinib-moves-toward-europe-approval-review\/","name":"Eisai and Nuvation Broaden Taletrectinib\u2019s EU Reach","isPartOf":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#website"},"primaryImageOfPage":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/taletrectinib-moves-toward-europe-approval-review\/#primaryimage"},"image":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/taletrectinib-moves-toward-europe-approval-review\/#primaryimage"},"thumbnailUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2026\/03\/Eisai-and-Nuvation-Bio-Announce-Marketing-Authorisation-Application-for-Taletrectinib-for-the-Treatment-of-Advanced-ROS1.webp","datePublished":"2026-03-27T10:44:58+00:00","description":"Eisai and Nuvation Bio advance taletrectinib in Europe as the European Medicines Agency validates the application.","breadcrumb":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/taletrectinib-moves-toward-europe-approval-review\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/itbusinesstoday.com\/health-tech\/pharma\/taletrectinib-moves-toward-europe-approval-review\/"]}]},{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/taletrectinib-moves-toward-europe-approval-review\/#primaryimage","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2026\/03\/Eisai-and-Nuvation-Bio-Announce-Marketing-Authorisation-Application-for-Taletrectinib-for-the-Treatment-of-Advanced-ROS1.webp","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2026\/03\/Eisai-and-Nuvation-Bio-Announce-Marketing-Authorisation-Application-for-Taletrectinib-for-the-Treatment-of-Advanced-ROS1.webp","width":1200,"height":800,"caption":"Eisai"},{"@type":"BreadcrumbList","@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/taletrectinib-moves-toward-europe-approval-review\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/itbusinesstoday.com\/"},{"@type":"ListItem","position":2,"name":"Taletrectinib Moves Toward Europe Approval Review"}]},{"@type":"WebSite","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#website","url":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/","name":"\u30a4\u30c3\u30c8\u30d3\u30b8\u30cd\u30b9\u30c8\u30a5\u30c7\u30a4","description":"","publisher":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Organization","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization","name":"\u30a4\u30c3\u30c8\u30d3\u30b8\u30cd\u30b9\u30c8\u30a5\u30c7\u30a4","url":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/","logo":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/logo\/image\/","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Asset-1.png","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Asset-1.png","width":663,"height":275,"caption":"itbusinesstoday"},"image":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/person\/94fb575e469aff25a4b938814d050f15","name":"ITBT\u30b9\u30bf\u30c3\u30d5\u30e9\u30a4\u30bf\u30fc","image":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Favicon-1.png90b3cb23d1d9c08733d969d29ea2d30d","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Favicon-1.png","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Favicon-1.png","caption":"ITBT StaffWriter"},"description":"ITBT\u30b9\u30bf\u30c3\u30d5\u30e9\u30a4\u30bf\u30fc\u306f\u3001IT Business Today\u306e\u793e\u5185\u5bc4\u7a3f\u8005\u3067\u3001\u30bf\u30a4\u30e0\u30ea\u30fc\u306a\u30cb\u30e5\u30fc\u30b9\u3068QuickBytes\u306e\u914d\u4fe1\u3092\u62c5\u5f53\u3057\u3066\u3044\u307e\u3059\u3002IT\u3001\u30cf\u30a4\u30c6\u30af\u3001\u4f01\u696d\u30bd\u30ea\u30e5\u30fc\u30b7\u30e7\u30f3\u306e\u6700\u65b0\u52d5\u5411\u3092\u30ab\u30d0\u30fc\u3057\u3001\u7c21\u6f54\u3067\u30a4\u30f3\u30d1\u30af\u30c8\u306e\u3042\u308b\u6700\u65b0\u60c5\u5831\u3092\u8aad\u8005\u306b\u63d0\u4f9b\u3057\u3066\u3044\u307e\u3059\u3002","sameAs":["https:\/\/itbusinesstoday.com\/"],"url":"https:\/\/itbusinesstoday.com\/ja\/author\/itbt-staffwriter\/"}]}},"authors":[{"term_id":572,"user_id":7,"is_guest":0,"slug":"itbt-staffwriter","display_name":"ITBT StaffWriter","avatar_url":{"url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Favicon-1.png","url2x":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Favicon-1.png"},"0":null,"1":"","2":"","3":"","4":"","5":"","6":"","7":"","8":""}],"_links":{"self":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/30530","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/comments?post=30530"}],"version-history":[{"count":1,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/30530\/revisions"}],"predecessor-version":[{"id":30532,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/30530\/revisions\/30532"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/media\/30531"}],"wp:attachment":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/media?parent=30530"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/categories?post=30530"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/tags?post=30530"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/ppma_author?post=30530"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}